|
Mar 21
|
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023
|
|
Mar 19
|
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
|
|
Mar 13
|
Harrow (HROW) Fell on Lowering the Guidance
|
|
Mar 5
|
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
|
|
Feb 15
|
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
|
|
Jan 11
|
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
|
|
Jan 3
|
Melt Pharmaceuticals Provides Corporate Update
|
|
Jan 3
|
Harrow Partners with Leading Healthcare Market Access Technology Platforms
|
|
Nov 29
|
Harrow Completes Transfer of the TRIESENCE® New Drug Application
|
|
Jul 19
|
Why Shares of Harrow Health Are Jumping Wednesday
|
|
Jul 19
|
Harrow Prices $60 Million Public Offering of Common Stock
|
|
Jul 18
|
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
|
|
Jul 18
|
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
|
|
Jul 18
|
Harrow Announces Proposed Public Offering of Common Stock
|
|
Jul 18
|
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
|